tutorial

MSI-High Colorectal Cancer Care Tech Platform Monitoring Guide 2026

"A comprehensive guide to monitoring digital health platforms supporting MSI-High colorectal cancer (MSI-H CRC) care, covering dMMR/MSI testing and Lynch syndrome cascade workflows, immunotherapy eligibility CDS, pembrolizumab first-line adherence, ctDNA surveillance, and hereditary cancer genetic counseling coordination."

MSI-High Colorectal Cancer Care Tech Platform Monitoring Guide 2026

Overview

Deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) status represents one of the most clinically significant biomarker categories in colorectal cancer. Approximately 15% of unselected CRC cases at diagnosis carry this designation, with the proportion weighted toward early-stage disease — roughly 20–25% of stage II–III CRC versus 3–5% of metastatic CRC. MSI-H tumors arise from failure of the DNA mismatch repair (MMR) system (proteins MLH1, MSH2, MSH6, PMS2), resulting in frameshift mutations at repetitive DNA sequences (microsatellites) and a hypermutated, immunogenic tumor microenvironment.

The clinical implications of MSI-H status in CRC are profound and span four distinct domains. First, MSI-H stage II CRC derives no survival benefit from adjuvant 5-fluorouracil — a paradoxical finding that makes biomarker-driven treatment decisions essential for this subgroup. Second, for metastatic MSI-H CRC, KEYNOTE-177 established pembrolizumab monotherapy as first-line standard of care over FOLFOX or FOLFIRI ± bevacizumab, with significantly improved progression-free survival and response duration. Third, approximately 15–20% of MSI-H CRC is attributable to Lynch syndrome (germline mutations in MLH1, MSH2, MSH6, or PMS2), which carries implications for colorectal, endometrial, ovarian, gastric, urothelial, and other malignancy surveillance across the patient and family members. Fourth, the POLE/POLD1 ultramutator phenotype produces a separate MSI-H-like hypermutated tumor with exceptional immunotherapy response — distinction from conventional dMMR is increasingly important for clinical trial stratification.

Care technology platforms supporting MSI-H CRC programs must coordinate biomarker testing and reflex ordering from the pathology sign-out, route Lynch syndrome findings to genetic counseling workflows, support immunotherapy CDS and adherence monitoring, manage ctDNA surveillance for minimal residual disease (MRD) assessment in resected patients, and coordinate multi-generational hereditary cancer cascade testing programs.

Care Technology Landscape

dMMR/MSI Testing and Reflexing Platforms — Standard of care requires universal dMMR/MSI testing of all newly diagnosed CRC at the time of initial pathologic diagnosis. Pathology information systems must support automated reflex ordering of IHC for MLH1, MSH2, MSH6, and PMS2 (and reflex MLH1 promoter methylation when MLH1 is lost on IHC) from the surgical pathology or biopsy sign-out. LIS results must populate structured OIS fields and trigger downstream Lynch syndrome germline testing recommendations. MSI PCR or next-generation sequencing-based MSI calling must be available as a reflex when IHC results are equivocal.

Lynch Syndrome Germline Testing Coordination Platforms — Patients with dMMR IHC result and absence of somatic MLH1 promoter methylation (or with any MSH2, MSH6, or PMS2 loss) require referral to genetic counseling for germline testing. Genetic counseling workflow systems must receive structured IHC results, generate automated germline testing referrals, and route confirmed Lynch syndrome diagnoses back to the oncology and gastroenterology systems to trigger enhanced surveillance protocols. Cascade testing platforms must identify first-degree relatives for outreach and guide family probands through germline panel testing.

Immunotherapy Eligibility and CDS Platforms — For metastatic MSI-H CRC, pembrolizumab first-line eligibility must be computed from the OIS biomarker record (MSI-H or dMMR confirmed, no prior anti-PD-1/PD-L1 exposure) and surfaced as a CDS recommendation at the treatment planning encounter. For resected MSI-H CRC patients, CDS logic must distinguish stage II (no adjuvant 5-FU benefit, consider surveillance vs. clinical trial) from stage III (adjuvant FOLFOX or CAPOX appropriate; biomarker does not negate benefit in stage III).

ctDNA and MRD Surveillance Platforms — Circulating tumor DNA (ctDNA) testing for MRD assessment is increasingly guideline-endorsed in resected stage II–III CRC. Laboratory platforms performing ctDNA (Guardant Reveal, Natera Signatera, or equivalent) must route results to the OIS, trigger enrollment decisions for ctDNA-guided adjuvant therapy protocols, and schedule serial testing at protocol-defined intervals. MSI-H patients on adjuvant trials may have distinct ctDNA surveillance protocols than microsatellite-stable (MSS) patients.

Hereditary Cancer Surveillance Program Systems — Confirmed Lynch syndrome patients require lifelong enhanced surveillance: colonoscopy every 1–2 years, annual endometrial biopsy/transvaginal ultrasound in female carriers, consideration of upper endoscopy and urinary cytology depending on mutation subtype. Surveillance program systems must encode Lynch syndrome-specific surveillance protocols, generate automated outreach, and maintain family pedigrees linked to the probandʼs oncology record.

Key Monitoring Metrics

dMMR/MSI Testing Completeness and Routing

Universal Testing Compliance

  • dMMR IHC (4-protein panel: MLH1, MSH2, MSH6, PMS2) ordered on all newly diagnosed CRC specimens: order completeness (target: 100%)
  • Reflex MLH1 promoter methylation ordered automatically when MLH1 IHC loss detected: reflex automation rate (target: 100%)
  • MSI PCR or NGS-based MSI called on all CGP panels for metastatic CRC: inclusion rate (target: > 95%)
  • Time from specimen receipt to dMMR IHC sign-out: target ≤ 5 business days

Result Routing and Structured Field Population

  • dMMR/MSI result routed to OIS structured biomarker field within 4 hours of sign-out: routing rate
  • Lynch syndrome candidate flag (dMMR without MLH1 methylation) generating genetic counseling referral order: trigger rate (target: 100%)
  • MSI-H result generating immunotherapy eligibility CDS alert in OIS: trigger rate (target: 100%)
  • POLE/POLD1 variant in CGP panel generating ultramutator flag for trial stratification: trigger rate

Lynch Syndrome Genetic Counseling Coordination

Referral Timeliness

  • Genetic counseling referral placed within 5 business days of Lynch syndrome candidate flag: referral timeliness (target: > 90%)
  • Genetic counseling visit completed within 30 days of referral: visit completion rate (target: > 80%)
  • Germline MMR panel test ordered at genetic counseling visit: order compliance (target: > 95%)

Confirmed Lynch Syndrome Cascade

  • Confirmed Lynch syndrome result routed back to oncology OIS and gastroenterology systems: cross-system routing rate (target: 100%)
  • Enhanced Lynch colonoscopy surveillance schedule encoded within 30 days of germline result: protocol creation rate (target: > 90%)
  • First-degree relative cascade testing outreach initiated within 60 days of proband confirmation: outreach initiation rate
  • At-risk relatives completing genetic counseling and germline testing: cascade completion rate (benchmark tracking)

Immunotherapy CDS and Pembrolizumab Adherence

Eligibility CDS

  • MSI-H or dMMR status in metastatic CRC triggering pembrolizumab first-line CDS alert at treatment planning encounter: trigger rate (target: 100%)
  • CDS alert acknowledged by oncologist within 2 business days: acknowledgment rate
  • MSI-H stage II CRC triggering alert that 5-FU adjuvant benefit is absent per NCCN guidelines: trigger rate (target: 100%)

Pembrolizumab Cycle Adherence

  • Pembrolizumab cycles delivered within ±14 days of planned date: on-time delivery rate (target: > 85%)
  • Pre-cycle LFTs (ALT, AST, bilirubin) and thyroid function (TSH) resulted before each cycle: pre-cycle lab compliance (target: > 90%)
  • irAE detection: grade ≥ 2 colitis, hepatitis, or endocrinopathy triggering hold and subspecialty consult order: trigger rate (target: 100%)
  • Progressive disease on pembrolizumab triggering second-line protocol assignment and CGP retest order: escalation rate

Response Assessment

  • CT chest/abdomen/pelvis restaging at 8–12 weeks after pembrolizumab initiation: imaging compliance (target: > 90%)
  • Hyperprogression pattern (> 50% tumor volume increase on first restaging CT) generating urgent oncologist review flag: trigger rate
  • Complete response documented generating surveillance schedule for pembrolizumab discontinuation consideration: documentation rate

ctDNA and MRD Surveillance

ctDNA Testing Completeness

  • ctDNA MRD test ordered at 4–6 weeks post-resection for resected stage II–III MSI-H CRC: order completeness (target: > 80%)
  • Serial ctDNA tests scheduled per protocol (every 3–6 months for 2 years post-resection): scheduling compliance
  • ctDNA result routed from laboratory to OIS structured field within 3 business days of sign-out: routing rate

MRD-Guided Decision Support

  • ctDNA positive result (MRD detected) at post-resection time point triggering adjuvant therapy or trial enrollment CDS: trigger rate (target: 100%)
  • ctDNA result integrated with CT restaging schedule: protocol coordination rate
  • ctDNA platform vendor result available within 14 calendar days of blood draw: vendor SLA compliance tracking

Lynch Surveillance Program Metrics

Protocol Adherence

  • Lynch colonoscopy performed within ±3 months of scheduled surveillance date: on-time rate (target: > 80%)
  • Female Lynch carriers with endometrial surveillance (annual biopsy or TVUS) completed: compliance rate
  • Upper endoscopy (MSH2 carriers, MLH1 with gastric family history) scheduled per subtype protocol: scheduling compliance
  • Patients overdue for Lynch surveillance by > 90 days: automated outreach trigger rate

Registry and Pedigree Maintenance

  • Proband Lynch syndrome record linked to family pedigree in registry: linkage rate (target: 100%)
  • Pedigree updated within 60 days of new family member diagnosis: update rate
  • At-risk relatives reaching age of first surveillance (typically 20–25 years) generating first colonoscopy outreach: outreach rate

Platform Setup

Observability Architecture for MSI-H CRC Platforms

# Prometheus scrape config for MSI-H CRC care platforms
scrape_configs:
  - job_name: dmmr_msi_testing_router
    static_configs:
      - targets: ['biomarker-router.internal:9090']
    scrape_interval: 30s

  - job_name: lynch_syndrome_coordinator
    static_configs:
      - targets: ['genetics-platform.internal:9090']
    scrape_interval: 120s

  - job_name: pembrolizumab_management
    static_configs:
      - targets: ['immunotherapy-platform.internal:9090']
    scrape_interval: 60s

  - job_name: ctdna_mrd_platform
    static_configs:
      - targets: ['ctdna-platform.internal:9090']
    scrape_interval: 300s

  - job_name: lynch_surveillance_scheduler
    static_configs:
      - targets: ['hereditary-cancer-sched.internal:9090']
    scrape_interval: 300s

dMMR Result Routing Canary

# Pseudocode: dMMR routing canary for MSI-H CRC
def run_dmmr_routing_canary():
    test_patient_id = "CANARY-MSI-H-CRC-001"
    inject_biomarker_result(
        patient_id=test_patient_id,
        test="MMR_IHC",
        result={"MLH1": "LOST", "PMS2": "LOST", "MSH2": "INTACT", "MSH6": "INTACT"},
        tumor_type="COLORECTAL"
    )
    start = time.now()
    ois_field = poll_for_ois_field(
        patient_id=test_patient_id,
        field="mmr_status",
        timeout=14400  # 4-hour SLA
    )
    latency = time.now() - start
    metrics.record("dmmr_routing_latency_seconds", latency)
    if ois_field is None:
        page_on_call("MSI-H CRC canary: dMMR IHC result not routed to OIS within 4-hour SLA")
    # Check Lynch syndrome candidate flag (MLH1 loss — needs methylation reflex)
    lynch_flag = check_cds_alert(test_patient_id, alert_type="mlh1_methylation_reflex")
    if not lynch_flag:
        alert_informatics_team("MSI-H CRC canary: MLH1 methylation reflex order not generated for MLH1-loss IHC")

Lynch Syndrome Cascade Automation

-- Auto-generate genetic counseling referral on Lynch candidate identification
CREATE OR REPLACE PROCEDURE process_lynch_candidate(patient_id UUID, mmr_ihc_result JSONB)
AS $$
DECLARE
  mlh1_methylated BOOLEAN;
BEGIN
  -- MLH1 loss without methylation = germline Lynch candidate
  IF (mmr_ihc_result->>'MLH1' = 'LOST') THEN
    SELECT methylated INTO mlh1_methylated
    FROM mlh1_methylation_results WHERE patient_id = patient_id
    ORDER BY resulted_at DESC LIMIT 1;

    IF mlh1_methylated IS FALSE OR mlh1_methylated IS NULL THEN
      INSERT INTO clinical_alerts (patient_id, alert_type, severity, message, created_at)
      VALUES (patient_id, 'LYNCH_SYNDROME_CANDIDATE', 'P2',
              'MLH1 loss without promoter methylation — germline Lynch syndrome testing referral required', NOW());
    END IF;
  END IF;

  -- MSH2, MSH6, PMS2 loss = always Lynch candidate
  IF (mmr_ihc_result->>'MSH2' = 'LOST' OR mmr_ihc_result->>'MSH6' = 'LOST' OR mmr_ihc_result->>'PMS2' = 'LOST') THEN
    INSERT INTO clinical_alerts (patient_id, alert_type, severity, message, created_at)
    VALUES (patient_id, 'LYNCH_SYNDROME_CANDIDATE', 'P2',
            'MSH2/MSH6/PMS2 loss on IHC — germline Lynch syndrome testing referral required', NOW());
  END IF;
END;
$$ LANGUAGE plpgsql;

ctDNA MRD Monitoring Pipeline

# Pseudocode: ctDNA MRD result processing for resected MSI-H CRC
def process_ctdna_result(patient_id, result):
    mrd_detected = result.get("mrd_detected")
    variant_allele_fraction = result.get("mean_tumor_fraction")
    time_point = result.get("time_point")  # e.g., "4_weeks_post_resection"

    route_to_ois_field(patient_id, field="ctdna_mrd", value=mrd_detected, time_point=time_point)
    metrics.record("ctdna_routing_latency_seconds", routing_latency())

    if mrd_detected:
        generate_cds_alert(
            patient_id=patient_id,
            alert_type="ctdna_mrd_positive",
            severity="P2",
            message=f"ctDNA MRD positive at {time_point} (VAF: {variant_allele_fraction:.4f}) — adjuvant/trial enrollment CDS active"
        )
    else:
        schedule_next_ctdna(patient_id, current_time_point=time_point)

Alerting Strategies

Severity Tiering

P1 — Immediate Clinical Impact

  • dMMR IHC result routing engine down; MSI-H status not reaching OIS or generating immunotherapy CDS
  • Pembrolizumab irAE monitoring system offline; grade ≥ 2 colitis or hepatitis not generating hold alerts
  • Lynch syndrome candidate flag system offline; MLH1 methylation reflex orders not generating
  • ctDNA result routing failure; MRD-positive results not reaching OIS or CDS within 3 business days

P2 — Degraded Operation

  • dMMR IHC result routing latency > 8 hours from sign-out
  • Genetic counseling referral generation rate for Lynch syndrome candidates < 85%
  • Pembrolizumab pre-cycle lab compliance < 85% week-over-week
  • ctDNA MRD surveillance scheduling compliance < 75% for resected stage II–III MSI-H cohort

P3 — Quality and Compliance

  • Universal dMMR testing order compliance < 95% for newly diagnosed CRC: LIS reflex audit
  • Lynch surveillance colonoscopy overdue rate > 15%: registry outreach audit
  • Stage II MSI-H 5-FU adjuvant non-benefit CDS alert acknowledgment < 80%: CDS workflow review

On-Call Escalation

  • Clinical informatics engineer (primary for P1 routing and platform failures)
  • Oncology pharmacist on call (pembrolizumab hold and irAE steroid decisions out of hours)
  • Genetic counseling program manager (Lynch cascade queue overflow and reflex order failures)

Notification Channels

  • P1: PagerDuty page + SMS to primary and secondary on-call
  • P2: Slack #msi-h-crc-informatics + email to GI oncology informatics lead
  • P3: Automated JIRA ticket to oncology informatics backlog; monthly Lynch cascade completion report to hereditary cancer program coordinator

Conclusion

MSI-H colorectal cancer sits at the intersection of precision immunotherapy, hereditary cancer genomics, and ctDNA-guided minimal residual disease monitoring — making it one of the most biomarker-dense and platform-dependent CRC subtypes to manage. The failure of any single routing link — dMMR IHC not reaching OIS, Lynch syndrome candidate not triggering germline referral, pembrolizumab irAE not generating a hold order — translates directly into missed treatment opportunities or preventable immune toxicity for patients and their families.

Engineering teams supporting MSI-H CRC programs should prioritize dMMR routing canary tests, Lynch syndrome cascade automation pipelines, and ctDNA result routing validation. With observability infrastructure tuned to the multi-domain complexity of MSI-H CRC care, digital health platforms provide the coordination backbone that transforms biomarker-driven oncology from a guideline recommendation into consistent clinical reality in 2026.

Monitor your app with Vigilmon

Free plan — 5 monitors, no credit card required. Up and running in 60 seconds.

Start free →
← Back to all articles